{
  "id": 5308171,
  "title": "Wells Fargo raises Phreesia stock price target on network growth",
  "url": "https://urgent.news/2026/09/03/wells-fargo-raises-phreesia-stock-price-target-on-network-growth",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T10:39:12.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/wells-fargo-raises-phreesia-stock-price-target-on-network-growth-93CH-4887455"
  },
  "original_language": "en",
  "account": "Wells Fargo has upped its price target on Phreesia Inc. stock to $10.00, maintaining an Equal Weight rating. Analyst Stan Berenshteyn highlighted that the company's second-quarter fiscal 2027 results generally met expectations. Revenue for the quarter was $129.5 million, closely aligning with Wells Fargo's estimates. Adjusted EBITDA came in at $32.9 million, surpassing projections by 8%. The margin of 25.4% exceeded projections of 23.5% and 23.6%, respectively. Phreesia, valued at $732 million, has seen a 14% revenue growth over the past year. The stock appears undervalued, trading below its Fair Value and is included in the list of Most Undervalued stocks. The Network segment showed a 9% year-over-year growth, driven by a ProviderConnect pilot that resulted in a 4% prescription lift in a GLP-1 campaign. Management noted that this pilot led to follow-on business. However, subscription revenue declined by 2% year-over-year, and AHCS grew by 3%. The company expects near-term concerns to include subscription pressure as they shift away from subscriptions to protect account growth, along with limited Network visibility and slow AccessOne traction. Despite these challenges, analysts predict the company will be profitable this year, with net income expected to grow. Phreesia Inc. reported a slightly better-than-expected revenue of $129.5 million for its fiscal second quarter of 2026, driven by growth in healthcare services clients and network solutions. However, adjusted earnings per share fell short of expectations, at $0.03 compared to the forecasted $0.09. Despite the revenue increase, the earnings miss and a cautious outlook weighed on investor sentiment, with no analyst upgrades or downgrades noted.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}